Pembrolizumab is a humanized immunoglobulin G4 monoclonal antibody that binds to programmed death receptor-1 (PD-1) on CD8+ T cells preventing interaction with programmed death ligand-1 (PD-L1) and PD-L2 on tumor cells. This evidence concerns the gene CD274 and neoplasm.